Walter M. Stadler to Orchiectomy
This is a "connection" page, showing publications Walter M. Stadler has written about Orchiectomy.
Connection Strength
0.540
-
The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J. 2016 Sep/Oct; 22(5):330-333.
Score: 0.142
-
Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014 Nov 26; 12:313.
Score: 0.126
-
Novel approaches and future directions in castration-resistant prostate cancer. Ann Oncol. 2011 Sep; 22(9):1948-1957.
Score: 0.097
-
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50.
Score: 0.030
-
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43.
Score: 0.029
-
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
Score: 0.025
-
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20; 29(30):4022-8.
Score: 0.025
-
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30.
Score: 0.025
-
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84.
Score: 0.021
-
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int. 2007 Jul; 100(1):70-5.
Score: 0.019